Kevin has been working with Index since 2003. He focuses on life sciences, especially drug development companies, and including Acutus Inc., B3NGF, Levicept Ltd and PanGenetics (acquired by Abbott). Prior to joining Index, Kevin was CEO of PanGenetics, a Netherlands-based antibody development company and Index investment. He was part of the team at Cambridge Antibody Technology (CAT), becoming head of research in 1994. In 1997 he was appointed to the board as Research Director and Chief Technology Officer. He led development of CAT's platform technologies and their application in the discovery of a number of human antibodies currently in clinical development. Two of these, Humira (Abbott Pharmaceutical) and Benlysta (HGS, GSK), are now on the market. He was part of the management team that floated CAT on the London Stock Exchange. Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.
- Holyhead, Anglesey
- Anglesey, Edinburgh, Cambridge
- Cambridge, Utrecht, Melbourne